During the past three decades, over thirty-five anti-HIV-1 therapies have been developed for use in humans and the progression from monotherapeutic treatment regimens to today’s highly active combination antiretroviral therapies has had a dramatic impact on disease prog... View more
De Clercq, E.. HIV inhibitors targeted at the reverse transcriptase.
AIDS Research and Human Retroviruses. 1992; 8 (2): 119-134
Molla, A., Richard Granneman, G., Sun, E., Kempf, D. J.. Recent developments in HIV protease inhibitor therapy.
Antiviral Research. 1998; 39 (1): 1-23
Ryser, H. J. P., Flückiger, R.. Keynote review: progress in targeting HIV-1 entry.
Drug Discovery Today. 2005; 10 (16): 1085-1094
Larder, B. A.. Viral resistance and the selection of antiretroviral combinations.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1995; 10: S28-S33
Mayers, D. L.. Drug-resistant HIV-1: the virus strikes back.
Journal of the American Medical Association. 1998; 279 (24): 2000-2002
Boden, D., Hurley, A., Zhang, L., Cao, Y., Guo, Y., Jones, E., Tsay, J., Ip, J., Farthing, C., Limoli, K., Parkin, N., Markowitz, M.. HIV-1 drug resistance in newly infected individuals.
Journal of the American Medical Association. 1999; 282 (12): 1135-1141
Murphy, R. L.. Defining the toxicity profile of nevirapine and other antiretroviral drugs.
Journal of Acquired Immune Deficiency Syndromes. 2003; 34 (1): S15-S20
Sabundayo, B. P., McArthur, J. H., Langan, S. J., Gallant, J. E., Margolick, J. B.. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
Pharmacotherapy. 2006; 26 (5): 674-681
Gallant, J. E., Dejesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J. J., Cheng, A. K.. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
The New England Journal of Medicine. 2006; 354 (3): 251-260